BACKGROUND: HIV-infected patients who fail to normalize CD4 T cells despite suppressive antiretroviral therapy have impaired immune homeostasis: diminished naive T-cell numbers, elevated T-cell turnover, senescence, and inflammation. METHODS: Blood samples from immune failures (n = 60), immune successes (n = 20), and healthy controls (n = 20) were examined for plasma interleukin (IL)-7 levels, for cellular expression of the IL-7Rα chain (CD127), for the exhaustion and senescence markers programed death 1 (PD-1) and CD57, and for the survival factor Bcl2. Because both inflammatory and homeostatic cytokines can induce T-cell cycling, we also examined the effects of these mediators on exhaustion and senescence markers. RESULTS: Plasma levels of IL-7 were elevated and both CD4 and CD8 T-cell CD127 expression was decreased in immune failure. Plasma levels of IL-7 correlated directly with naive CD4 T-cell counts in immune success and inversely with T-cell cycling (Ki67) in healthy controls and immune success, but not in immune failure. CD4 T-cell density of PD-1 was increased and Bcl2+ CD4 T cells were decreased in immune failure but not in immune success, whereas the proportion of T cells expressing CD57 was increased in immune failure. PD-1 and CD57 were induced on CD4 but not CD8 T cells by stimulation in vitro with inflammatory IL-1β or homeostatic (IL-7) cytokines. CONCLUSIONS: Perturbation of the IL-7/IL-7 receptor axis, increased T-cell turnover, and increased senescence may reflect dysregulated responses to both homeostatic and inflammatory cytokines in immune failure patients.
BACKGROUND:HIV-infectedpatients who fail to normalize CD4 T cells despite suppressive antiretroviral therapy have impaired immune homeostasis: diminished naive T-cell numbers, elevated T-cell turnover, senescence, and inflammation. METHODS: Blood samples from immune failures (n = 60), immune successes (n = 20), and healthy controls (n = 20) were examined for plasma interleukin (IL)-7 levels, for cellular expression of the IL-7Rα chain (CD127), for the exhaustion and senescence markers programed death 1 (PD-1) and CD57, and for the survival factor Bcl2. Because both inflammatory and homeostatic cytokines can induce T-cell cycling, we also examined the effects of these mediators on exhaustion and senescence markers. RESULTS: Plasma levels of IL-7 were elevated and both CD4 and CD8 T-cell CD127 expression was decreased in immune failure. Plasma levels of IL-7 correlated directly with naive CD4 T-cell counts in immune success and inversely with T-cell cycling (Ki67) in healthy controls and immune success, but not in immune failure. CD4 T-cell density of PD-1 was increased and Bcl2+ CD4 T cells were decreased in immune failure but not in immune success, whereas the proportion of T cells expressing CD57 was increased in immune failure. PD-1 and CD57 were induced on CD4 but not CD8 T cells by stimulation in vitro with inflammatory IL-1β or homeostatic (IL-7) cytokines. CONCLUSIONS: Perturbation of the IL-7/IL-7 receptor axis, increased T-cell turnover, and increased senescence may reflect dysregulated responses to both homeostatic and inflammatory cytokines in immune failurepatients.
Authors: Marco Marziali; Wladimiro De Santis; Rossella Carello; Wilma Leti; Antonella Esposito; Antonella Isgrò; Caterina Fimiani; Maria C Sirianni; Ivano Mezzaroma; Fernando Aiuti Journal: AIDS Date: 2006-10-24 Impact factor: 4.177
Authors: Sonia Fernandez; Patricia Price; Elizabeth J McKinnon; Richard C Nolan; Martyn A French Journal: Clin Immunol Date: 2006-06-09 Impact factor: 3.969
Authors: Cheryl L Day; Daniel E Kaufmann; Photini Kiepiela; Julia A Brown; Eshia S Moodley; Sharon Reddy; Elizabeth W Mackey; Joseph D Miller; Alasdair J Leslie; Chantal DePierres; Zenele Mncube; Jaikumar Duraiswamy; Baogong Zhu; Quentin Eichbaum; Marcus Altfeld; E John Wherry; Hoosen M Coovadia; Philip J R Goulder; Paul Klenerman; Rafi Ahmed; Gordon J Freeman; Bruce D Walker Journal: Nature Date: 2006-08-20 Impact factor: 49.962
Authors: Angélique Biancotto; Jean-Charles Grivel; Sarah J Iglehart; Christophe Vanpouille; Andrea Lisco; Scott F Sieg; Robert Debernardo; Kristen Garate; Benigno Rodriguez; Leonid B Margolis; Michael M Lederman Journal: Blood Date: 2007-02-08 Impact factor: 22.113
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Marie R McCausland; Angélica Cruz-Lebrón; Heather A Pilch-Cooper; Scott Howell; Jeffrey M Albert; Young S Park; Alan D Levine Journal: AIDS Date: 2020-05-01 Impact factor: 4.177
Authors: Souheil-Antoine Younes; Michael L Freeman; Joseph C Mudd; Carey L Shive; Arnold Reynaldi; Soumya Panigrahi; Jacob D Estes; Claire Deleage; Carissa Lucero; Jodi Anderson; Timothy W Schacker; Miles P Davenport; Joseph M McCune; Peter W Hunt; Sulggi A Lee; Sergio Serrano-Villar; Robert L Debernardo; Jeffrey M Jacobson; David H Canaday; Rafick-Pierre Sekaly; Benigno Rodriguez; Scott F Sieg; Michael M Lederman Journal: J Clin Invest Date: 2016-06-20 Impact factor: 14.808
Authors: Michael L Freeman; Carey L Shive; Thao P Nguyen; Souheil-Antoine Younes; Soumya Panigrahi; Michael M Lederman Journal: J Infect Dis Date: 2016-10-01 Impact factor: 5.226
Authors: Thao P Nguyen; Supriya Shukla; Robert Asaad; Michael L Freeman; Michael M Lederman; Clifford V Harding; Scott F Sieg Journal: AIDS Date: 2016-08-24 Impact factor: 4.177
Authors: J M Eberhard; F Ahmad; H S Hong; N Bhatnagar; P Keudel; J Schulze Zur Wiesch; R E Schmidt; D Meyer-Olson Journal: Clin Exp Immunol Date: 2016-08-23 Impact factor: 4.330
Authors: Souheil-Antoine Younes; Aarthi Talla; Susan Pereira Ribeiro; Evgeniya V Saidakova; Larisa B Korolevskaya; Konstantin V Shmagel; Carey L Shive; Michael L Freeman; Soumya Panigrahi; Sophia Zweig; Robert Balderas; Leonid Margolis; Daniel C Douek; Donald D Anthony; Pushpa Pandiyan; Mark Cameron; Scott F Sieg; Leonard H Calabrese; Benigno Rodriguez; Michael M Lederman Journal: J Clin Invest Date: 2018-10-15 Impact factor: 19.456